Target intelligence / Profile preview

Second Mitochondria-Derived Activator of Caspases (SMAC)

Target: SMAC
Molecular classification: Protein, Mitochondrial protein

Overview

SMAC is a mitochondrial protein that promotes apoptosis by antagonizing the inhibitory effects of IAPs on caspases. Upon apoptotic stimuli, SMAC is released into the cytosol and binds to IAPs, facilitating caspase activation and cell death. SMAC mimetics are being developed as cancer therapeutics to enhance tumor cell susceptibility to apoptosis.

Other names: DIABLODirect IAP-Binding protein with Low PI

Mechanism of action

SMAC mimetics bind to IAPs, neutralizing their inhibitory effect on caspases, thereby promoting apoptosis.

Biological functions

ApoptosisRegulation of apoptosisCaspase activationInhibition of IAPs

Disease associations

Cancer

Interacting drugs

SMAC mimetics

Beyond the preview

Go deeper on Second Mitochondria-Derived Activator of Caspases (SMAC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Second Mitochondria-Derived Activator of Caspases (SMAC).

Explore the full profile